
Execution Beats Flashy Funding
Interview with AccurKardia CEO Juan C. Jimenez
About the Guest
Juan C. Jimenez started as an investment banker specializing in M&A transactions, then moved on to become President of Puerto Ricoโs largest non-emergency medical transportation company, TransCita. Now, as a medtech founder, heโs making waves in the ECG diagnostics space with AccurKardia. Leveraging his background in finance and healthcare, Juan brings unique expertise on efficiency and scale for medtech startups.
Interview Summary
Juan C. Jimenez began his career in finance and investment banking, specializing in M&A transactions at Credit Suisse. After the 2008-2009 financial crisis, he pivoted to real estate distressed credit investment, which led him to a surprising role as President of a non-emergency medical transportation company. This was his first exposure to healthcare, and it left a lasting impression. โHelping people and improving patient outcomes is what drives me,โ Juan says, realizing heโd found a space he wanted to stay in.
AccurKardia began with a casual suggestion from a friend (and now also Co-Founder of AccurKardia) and turned into a full-time endeavor for Juan when he saw its life-saving potential. โI got involved, I invested, and fell in love with the technology and the fact that we could literally save lives,โ Juan recalls.
AccurKardia, founded in 2019, addresses a major gap in cardiac monitoring: automating ECG interpretation. Theyโve built a device-agnostic platform that analyzes ECG data from various devices, such as Holter monitors and mobile cardiac telemetry, providing actionable insights for physicians more quickly and cost-effectively than traditional methods.
Typically, data collected from these devices is sent offshore for analysis, delaying results and creating variability in quality. AccurKardiaโs automated platform allows healthcare providers to keep data onshore, reducing interpretation times and improving care quality. As Juan explains, โMost of the ECG data obtained in the U.S. is not reviewed by cardiac monitoring companies. Our product is meant to keep that data onshore and improve the quality of interpretation, allowing doctors to get data faster so they can initiate treatment promptly.โ
AccurECG, the companyโs first FDA-cleared product is already making waves, with one paying customer onboard and several more in the pipeline. Theyโve also achieved breakthrough designation for a new model that screens for aortic stenosis, a condition often overlooked in asymptomatic patients. โThere are 100 million ECGs performed in the U.S. per year,โ Juan points out. โIf we can screen with that data, we can identify asymptomatic patients with aortic stenosis, improving their quality of life by catching the issue early.โ
Looking ahead, AccurKardia has a robust product pipeline that includes novel use cases for ECG data, such as detecting cardiac amyloidosis, electrolyte dysfunction, and heart failure. With another FDA filing planned for 2025, Juan is optimistic. โThe accuracy of our cardiac monitoring product is already deployed, and we hope to have four or five more customers soon. Saving lives through earlier, better management of patients is what I love.โ
Key Learnings From Juanโs Experience
Capital efficiency can often be more valuable than flashy, oversized funding rounds. Focus on scaling sustainably without unnecessary dilution by keeping your organization lean and focused. And donโt forget to make that a point of emphasis for your company as it will make finding capital that much easier.
Focus on developing your product and thoroughly understanding your market before inviting investors to join your venture. Allow your team space to develop a solid foundation before bringing in external opinions to ensure that early investor feedback doesnโt misalign or dilute your core vision.
Prioritize genuine relationships, transparency, and rigorous standards to build credibility and lasting partnerships. Be upfront about both your strengths and limitations. Embrace a proactive approach to validation and industry recognition, particularly if youโre an unconventional player in the field.
Capital Efficiency Beats Big Valuations
โIn medtech, fast is never an option,โ says Juan. Medtech has a painstaking pace. Here, even software development can be held up by regulatory requirements. Coming from a different background, Juan had to โlearn from scratchโ that while itโs crucial to keep moving, itโs even more important to move efficiently, ensuring each step advances the companyโs goals.
Starting with less than $6 million in funding, Juanโs initial expectation that he could build the company quickly turned out to be naive. As he notes, the pace in this space is often โslow, slower, or stop.โ However, his finance background had given him a strict focus on resource management. Rather than raise large sums of capital early, AccurKardia focused on using its limited funds wisely to achieve critical milestonesโan approach that he believes has been a major advantage.
โOur secret sauce is that we have been able to improve the process in which we take an idea and turn it into reality in a streamlined way," he explains. His goal is to build value first, so that when AccurKardia goes to market, funds can be used directly for commercialization rather than exploratory research. He says. โIf you're staring down $50 million in capital to get to a point where you're actually selling product, if 80% of that capital was used in the development versus maybe the opposite, where 80% is now being used to commercialize it, there's going to be a much stronger ROI in the latter scenario.โ This approach keeps AccurKardia nimble, lean, and competitive.
Thanks to his background in finance, Juan has a transactional, comparison-based view of progress. He is always aware of competitors and their capital raises but remains grounded in AccurKardiaโs own accomplishments. During the high valuations of 2021-2022, he decided not to pursue large rounds. "We used the money where we had to," he notes. This allowed them to avoid unnecessary dilution early on. Moreover, he used AccurKardiaโs efficient use of capital as a selling point to investors. This way, instead of competing for funds, he showed investors how AccurKardia had achieved more on a fraction of the budget that other companies have raised.โIf youโre in the position where youโve been really efficient, make that a strong point,โ he advises.
When and How to Engage with Investors
One of the things Juan learned from his journey in medtech was the importance of timing when bringing investors on board. For him, it was crucial to give his team time to develop their product and learn the market independently. He explains, โSometimes itโs good to let the innovators think on their own without too many opinions from outsiders who may not be experts.โ By working initially on their own terms, Juan and his team could refine their vision and prepare a strong foundation before inviting outside perspectives to help them scale. This also allowed them to tell a more genuine version of their story when they were ready for broader investor engagement.
However, this doesnโt mean you donโt need any funds to start. When it comes to raising, itโs important to remember that early fundraising tends to be relationship-based. Juan shares, โThe first few checks come from people that know you, people that know that failure is not an option for you.โ He and his team leveraged the credibility they had built over their careers to secure this early support. โIn our case, most of AccurKardiaโs co-founders came with accomplished backgroundsโwhether in banking, scaling companies, consulting, or building large enterprise-scale software platforms,โ he says. With this foundation, they were able to approach early investors with proven track records: โWe had the experience to show,โ he notes, โand that helped us secure our first few million.โ For those without established networks, Juanโs advice is to look into angel groups, crowdfunding, or grant programs, which can help fill that gap when traditional funding avenues arenโt immediately accessible.
Apart from being relationship-based, Juan shares, โAt the seed and pre-seed stage itโs very personal,โ meaning that rejections are often based on alignmentโor lack thereofโbetween an investorโs personality or vision and the founderโs own. Early-stage investors are not just assessing the product or potential market; theyโre also considering their rapport with the founder and whether the relationship feels right. Accepting this subjectivity can play a major roleโsome will find you and your mission close to theirs, and others wonโt.
That is why itโs essential to be โstubborn enoughโ to keep seeking funding despite repeated rejections. Even great ideas donโt always fit an investorโs โpattern,โ which is why Juan suggests founders be prepared to look at alternative funding sources if needed.
The Great, the Good, and the Ugly
Reflecting on AccurKardiaโs relationship with Lucem Health, Juan explains that it developed organically after they met through the Mayo Clinic Platform Accelerate program. โWe started to build a relationship, same as with investors and customers,โ he says. These connections, like all successful partnerships, grew over time. Seeing them as collaborations that need a personal foundation to evolve into something valuable (rather than transactions), helps you build a strong foundation. Thatโs how AccurKardiaโs first partner became their first commercial client and also expanded their productโs use cases in ways they hadnโt anticipated. Looking back, he says, โWhen they (Lucem Health) had a product they wanted to build to manage risk for stroke, and they needed a solution to analyze ECGs, we were the first people they called.โ
A lesson that goes hand-in-hand with relationship building is transparency. Juan stresses that sharing both the โgreat, the good, and the uglyโ with partners is essential, especially for an early-stage company. โIf you try to hide it or put some makeup on it,โ he warns, โyouโre going to be seen as dishonest.โ For Juan, transparency means acknowledging the productโs current limitations while emphasizing its strengths. Juanโs honesty has added to his credibility and allowed AccurKardia to build a solid pipeline of partnershipsโeven if some may need to pause while features are developed or refined.
As a startup team without traditional medtech backgrounds, Juan has also realized the value of accelerator programs in building credibility. MedTech Innovator and Mayo Clinic Platform Accelerate offered AccurKardia brand association, access to mentorship, and access to data. โAnyone in medtech must apply to MedTech Innovator. Itโs a rite of passage if you are in this space,โ Juan says. Especially for software-focused startups, accelerators are invaluable in bridging gaps in experience and gaining recognition in an industry that often favors hardware-based innovation.
To further bolster AccurKardiaโs credibility, Juan has taken clinical validation very seriously, acknowledging that his non-medtech background requires him to โoverdo itโ to prove his productโs reliability. For their FDA submission, they ran a validation study with a sample size four times larger than required, showing a commitment to high standards. โWe have to overdo it,โ Juan explains, emphasizing that robust data is their way of showing the industry and their customers the true capabilities of their technology.
Sponsors
FastWave Medical: Named MD+DI's Company of the Year, FastWave is one of the hottest medtech startups in the cardiovascular space. See how you can invest here.
Fundraising Cohort: Planning to raise capital for your startup? This live, 4-week workshop, led by Scott Nelson, is designed to help founders and CEOs tell a sharper story, get investor meetings that matter, and close real capital. Join the waitlist here.
Donโt Forget
Interested in advertising with us?
Get in Touch โ
Want to learn from more startup CEOs?
Check Out the Archive โ
Forwarded this email?
Join for Free โ
Who's Scott Nelson again?
See His Bio โ
Transcript
0:00:00 [upbeat music] I guess the best way to think about it from my standpoint is if you're staring down a $50 million in capital to get to a point where you're actually selling product, if 80% of that capital was used in the development versus maybe the opposite, or 80% is now being used to actually commercialize it, there's, there's gonna be a much stronger ROI in the latter scenario.
0:00:19 Welcome to MedSider, where you can learn from the brightest founders and CEOs in medical devices and health technology.
0:00:27 Join tens of thousands of ambitious doers as we unpack the insights, tactics, and secrets behind the most successful life science startups in the world. Now, here's your host, Scott Nelson. Hey everyone, it's Scott.
0:00:40 In this episode of MedSider, I sat down with Juan Jimenez, CEO of AccuCardia.
0:00:44 Juan started as an investment banker specializing in M&A transactions, then moved on to become president of Puerto Rico's largest non-emergency medical transportation company, Transita.
0:00:52 Now, as a med tech founder, he's making waves in the ECG diagnostic space with AccuCardia. Leveraging his background in finance and healthcare, Juan brings unique expertise on efficiency and scale for med tech startups.
0:01:03 Here are a few of the key things that we discussed in this conversation. First, capital efficiency can often be more valuable than flashy, oversized funding rounds.
0:01:11 Focus on scaling sustainably without unnecessary dilution by keeping your organization lean and focused.
0:01:17 And don't forget to make that a point of emphasis for your company, as it will make finding capital that much easier.
0:01:23 Second, focus on developing your product and thoroughly understanding your market before inviting investors to join your venture.
0:01:29 Allow your team space to develop a solid foundation before bringing in external opinions to ensure that early investor feedback doesn't misalign or dilute your core vision.
0:01:38 Third, prioritize genuine relationships, transparency, and rigorous standards to build credibility and lasting partnerships. Be upfront about both your strengths and limitations.
0:01:48 Embrace a proactive approach to validation and industry recognition, particularly if you're an unconventional player in the field. All right, quick note before we jump in.
0:01:56 If you're a MedSider listener, I'm guessing you're pretty serious about leveling up your game, right?
0:02:01 Well, if that's you, we just made MedSider Premium better than ever with our recent site relaunch, and I think you're gonna love what we've added. Here's the scoop.
0:02:07 With MedSider Playbooks, you've got thematic collections of hard-won insights from some of the brightest founders and CEOs in our space, covering topics like fundraising, risk management, regulatory reimbursement, you name it.
0:02:18 In MedSider Mentors, these are e-book volumes full of best practices and insider secrets from the same top-notch founders and CEOs that join our program, all downloadable for easy access.
0:02:28 Then there's the popular investor database that now includes over 750 life science VCs, family offices, corporate investors, and angels.
0:02:35 You see, raising capital can be one of the most grueling aspects of running a startup. So we created three custom packages.
0:02:40 Whether you need just the database or you want us to manage investor outreach for you, the MedSider team is ready to support your next fundraise. Just head over to medsider.com/investors and send us a note.
0:02:51 And don't forget, MedSider Premium members get access to every single interview dating back to 2010. That's over 200 episodes packed with expert insights from proven founders and CEOs.
0:03:01 So if you're ready to dive into all of this, check it out at medsider.com/subscribe. All right, let's jump into the episode. [upbeat music] All right, Juan, welcome to MedSider Radio.
0:03:13 Appreciate you carving out a little time in your otherwise busy schedule to make this happen. Thank you, Scott, for having me. Excited of being here. Yeah, this should be a, this should be a lot of fun.
0:03:21 So with that said, first question on the docket is, give us a-- without getting too far into the weeds, because we'll certainly use the next thirty, forty-five minutes to go back in time.
0:03:28 I wanna learn a little bit more about your journey from a recovering, recovering consultant, if you will, to founding, founding a startup.
0:03:35 But give us a high-level sense and elevator pitch of your professional career leading up to starting the company. I got into healthcare by accident initially, and then I got into tech startup by a friend.
0:03:46 But I started my career in investment banking, doing M&A capital markets transactions in a now-defunct bank called Credit Suisse, [chuckles] acquired by UBS just a few, a year and a half ago.
0:03:57 Traditional capital markets, M&A transaction, junior banker that then the 2008-2009 crisis hit, and then I moved to do some real estate distressed credit investment.
0:04:11 And I was recruited to be the CEO of a large non-emergency medical transportation company.
0:04:19 It was weird why they wanted to bring someone with a more financial background, and the shareholders of that company wanted to bring someone with an, with a more financial engineering perspective to be able to take the company and grow that company.
0:04:32 So I helped scale that company from, uh, uh, five X in terms of revenue. And when I left the firm, I was managing around seven hundred people, and I had a agreement with most of the commercial payers, Medicare, Medicaid.
0:04:50 And, and that's where by accident, I got in, I got in love with the healthcare.
0:04:54 As it, for me, right now, I don't see myself in other sector because building shareholder value, but at the end, helping people and helping life and improving patient outcomes is what drives me and get me motivated.
0:05:05 So then I, one of my best friends from business school wanted to start a company that became AccuCardia.
0:05:11 I got involved, I invested, fell in love with the technology and the use case, and the fact that, that we could literally save life with technology, and that's how I got into here. Yeah, that's awesome.
0:05:23 I love the kind of the, the atypical kind of backgrounds for founder CEOs like yourself. It should be, uh, I, I think fun to lean, lean into that throughout the rest of the discussion.
0:05:31 AccuCardia, you started, it looks based on your LinkedIn profile, you started it back in early 2019, so, so pre-COVID. We're recording this in late '24, so it's been roughly half a decade or so in, in the making.
0:05:42 Give us a high-level sense for kind of your, your, uh, y- your products as well as where you're at in terms of, in terms of life cycle.
0:05:50 In AccuCardia, what we have built is an ECG interpretation platform to, to fully automate the cardiac technician interpretation for the traditional Holter, extended Holter, a mobile cardiac telemetry in a device-agnostic manner.
0:06:06 And also leverage ECG As a broad biomarker with implications for the OEM beyond.
0:06:13 We believe ECG can give more information than is currently used for, and we are sitting on millions of data points from patients, and we can help identify, screen, and manage disease, uh, more efficiently and, and improving outcomes than before.
0:06:29 In terms of product development, we have one FDA cleared product, AccuECG, which is a Class II software as medical device.
0:06:38 We- w- which device agno- which device agnostic and can integrate with hol-- with FDA cleared Holter, extended Holter, and mobile cardiac telemetry.
0:06:47 And that product is meant to help cardiac monitoring companies in-- reduce interpretation time, improve margins, and deliver more quality in the interpretation component.
0:06:59 I don't know if you're aware, but most of the ECG Holter, extended Holter, MCT data obtained nowadays in the US, they are not reviewed by the cardiac monitoring company.
0:07:08 Most of that data is outsourced, sent offshore for cardiac technician labs to be analyzed, and our product is meant to kept onshore that data and improve the quality of that interpretation.
0:07:19 So therefore, doctors could get data faster, so they can initiate treatment promptly. And that's in a nutshell of that product.
0:07:27 We just obtained breakthrough device designation for our model to screen for aortic stenosis, just where in TCP a few days ago.
0:07:35 And, and, uh, we, um, and y- I, I bet you, you, you follow the new, um, clinical trial study announced about the value of, of treating severe or asymptomatic aortic stenosis patient.
0:07:48 And how can you find asymptomatic patients without the ubiquity, the help of the ubiquitous ECG?
0:07:55 We're sitting on-- There are a hundred million ECGs performed in the US per year, and if we can help screen with that, with that data, screen for patients, we'll be able to identify asymptomatic patients with aortic stenosis, and they could be directed to treatment, therefore improving the quality of life of that population.
0:08:13 But that's in a nutshell what we have. One FDA cleared product already c- with one paying customer and a few others knock on wood in the next few weeks. And a second product with breakthrough device designation.
0:08:25 Hopefully, we file, um, for clearance in mid twenty-twenty-five, and we have a few other use cases in the pipeline, leveraging ECG for novel use cases like cardiac amyloidosis, uh, electrolyte dysfunction, cardiomyopathy, and heart failure, et cetera.
0:08:42 Got it. Got it. Super helpful.
0:08:43 I wanna ask you a follow-up question on current state of, of kind of ECG monitoring that you, that you mentioned just 'cause I, I don't fully, I don't think I fully understood that previously.
0:08:52 But AKA AVS, what, the, the kind of the, the, the aortic stenosis screening tool that you just touched on, breakthrough designation, congrats on that, by the way. That's like not [laughs]
0:09:00 that's not-- Tho- those aren't easy to get, right? There's very few of those, uh, awarded these days, so that's, that's pretty cool news.
0:09:05 But does that-- Just so I understand that, does that-- Is that part of the software as a medical device platform then? Yes. That too. Yeah. Yeah.
0:09:12 That, that is a different use case of our platform to, to, to ingest ECG data, what we call for traditional use case, which is the typical arrhythmia management with Holter and the Holter MCT and novel use case.
0:09:26 And the first use case that we are going to novel is aortic stenosis screening using ECG is currently the gold standard is pursuing two approaches, auscultation, which is a dying art form, having a doctor listening to your heart, and if the, if there is, if the aortic stenosis is absent of a murmur, that'll be very difficult to find, or echocardiography.
0:09:47 And not every patient on risk gets an echo. So our product fits in the middle of auscultation and echo, and leveraging ECG is already obtained in the clinical workflow.
0:09:59 Our, our proposal is you don't need to get or prescribe new ECGs.
0:10:06 Let's use data already stored in the electronic medical record or already stored in the ECG repositories, scan for that data, and let's find patients with moderate to severe stenosis so they could be followed up and be directed to treatment when time comes.
0:10:22 Okay. Got it. And I guess that's a nice transition into kind of current standard of care. You mentioned that most interpretation analysis is outsourced these days then, and if... Is that correct?
0:10:32 And for the traditional use on the Holter extended Holter use case, that data is outsourced either onshore or offshore services.
0:10:40 The way industry have managed the redu- the reduction in reimbursement rates for Holter, extended Holter, and also the fact that these devices are becoming smaller, capable of recording more and more data, the way to manage that, that, uh, demand for, for analysis as well as re- reimbursement rate reduction has been outsourcing that, that analysis.
0:11:03 So either cardiac technician labs in the US or cardiac technician labs abroad, mostly in Southeast Asia, Far East Asia, or even Eastern Europe, performing that analysis to assist in this particular workflow.
0:11:18 And this data, th- this process can take days to even several weeks because of the, of the, of backlog of data.
0:11:27 So software is meant to solve this problem, to manage the growing demand, improving consistency, and keeping the data onshore. Got it. Okay. That's super helpful.
0:11:35 And so your software, does it sit then an Epic kinda EMR then? Is that kind of where it-- That's like pragmatically how this works is, right, like da- data's in an EM- E-E-EMR, and your software is kind of part of that.
0:11:46 It de- it depends on the use case. For long duration, ECG will be very difficult to coexist in the traditional EMR setting. For the novel use case, that could be a, a good solution.
0:11:58 But on the longer recordings, long duration, it has to be deployed in a cloud environment, traditional providers like AWS, Google Cloud, which are our preferred cloud providers, but it could also be compatible with Azure, etc.
0:12:12 Okay. Cool. That's very helpful. And I'm looking at the website now- Accur Kardia, A-C-U-R-K-A-R-D-I-A, accurkardia.com. We'll link to it in the full write-up on MedSider.
0:12:22 For those listening that wanna learn a little bit more about, about the technology and the various indications that are either cleared or that Juan and his team are working on, definitely encourage you to check out that site.
0:12:30 It's Accur Kardia-- Accur Kardia, A-C-C-U-R-K-A-R-D-I-A.com. And again, we'll link to it in the full write-up.
0:12:37 So Juan, with that said, let's spend the next half hour or so kind of running through some kind of various functions that most, most startups have to, have to nail, right, in order to achieve a certain level of success.
0:12:46 And the, the first one, I guess the first kind of topic I wanted to cover though is really your more, more your background, what-- which is a little bit atypical. Not a little bit, but fairly atypical, right?
0:12:55 You-- most medtech startups are founded by an engineer or a physician or maybe a commercial guy that's been around for a while. But you have a unique background, right?
0:13:04 You started in investment banking, then ran a, a very large-- I'm not sure the best way to- A medical transportation company. Yeah. In Transita. So yeah, it's just different.
0:13:14 And I'd love to learn a little bit more about how kind of those unique experiences have parlayed into Accur Kardia, and what are some key things that have helped really drive your success at Accur Kardia over the past half, half decade.
0:13:27 I, I think, I think that what you learn when you start a career and as a junior ba-- investment banker is the rigor, the attention to detail, and working harder than anyone else. I think it's...
0:13:40 And, and typically as a junior banker, you work even within this-- if you're part of an industry, you work with different companies, and not all companies are the same.
0:13:49 So you have to deep dive and become an expert very quickly in different sectors, different industry, different companies. So I think that cur-- intellectual curiosity of g- becoming
0:14:00 not even an expert, becoming knowledgeable enough to become dangerous in different sectors, it's what, what ha-have helped me become smarter on the cardiac monitoring space, in particular the ECG interpretation component, how to use ECG.
0:14:16 But given that I am-- I do not come from a traditional background, for me, the-there is-- there are no dogmas that can be challenged.
0:14:23 I think all of them can be challenged other than improving patient outcome, patient safety, and quality, right?
0:14:31 But for me, any particular dogma can be challenged and has to be challenged to see i-if I have followed the traditional use case, I wouldn't have been the place that we are today.
0:14:44 Just to give you an example, when I started a company five and a half years ago, my first trip to the Bay Area to introduce myself to the many players in the space, investors,
0:14:56 the consensus was this problem has be-- had been solved. There was no issue with it. And fast forward five years later, it's, it's a different dynamic. It's a different dynamic.
0:15:08 Everyone see the need, everyone see the, the, the importance of this. And for me, given that I'm not part-- I wasn't part of the status quo, I was able to classify noise
0:15:21 with the true signal and be able to follow that signal that led me to where I'm here today. Yeah, that's a, that's such a good point.
0:15:27 In fact, I think, I think our ecosystem need, needs more entrepreneurs like yourself that aren't afraid to buck the trend, right? Press up against certain dogma that's existed for a long time.
0:15:36 And if we're really expecting to see more innovation in this kind of fundraising environment, it takes people like you to view things from a different perspective.
0:15:43 But y- that, that, that's interesting though, because five years ago, I think a lot of entrepreneurs, they kept hearing, "No. We don't think this need exists," right? "No, we don't really think this is a big problem."
0:15:53 But you stuck to it. You knew it was a, a clear need.
0:15:56 And I think that hits home for me because I've seen that firs-firsthand in, in my journey as well, is that if you do tr- truly fundamentally believe this is a problem that should be solved for and it's, it's a big enough market, like, you have to cross that, that chasm a little bit and stick to your guns.
0:16:10 And was that-- has that been difficult? Or, like, how did you overcome, overcome some of those-- some of the, the inherent sort of self-doubt, right, that comes along with hearing so many no's, uh...
0:16:20 I think on one side, you hear the many no's, but on the other side, you see the, the effects of the status quo. Mm. Cardiovascular disease continue to be the leading cause of death in the US.
0:16:31 Life expectancy for the first fi-- first time in seventy-five years decrease in the US. There are fifty percent of counties in the US without a practicing cardiologist.
0:16:41 The, the cardiac, cardiac monitoring devices become s- better, smaller, being able to capture more and more data.
0:16:49 So the workflow that was fi- fi-- established five years ago, having sending data offshore, having humans taking a look, it, it wasn't efficient. It wasn't producing great outcomes.
0:17:00 So it's just a matter of time for that to happen.
0:17:03 And, and given that everything in healthcare takes time because you need to prove efficacy as well as safety and going through a regulatory process in the US, it takes time and resources.
0:17:13 So luckily, we were able to, to have a strong, patient investor base that helped us navigate through a regulatory process, be able to obtain clearance, and also dealing with the regulator, which in a domain that is changing, evolving.
0:17:29 If you had a pr- device cleared five years ago and you're going now, the, the, the, the bar is much higher, and it continues to become higher. So all that, all those things align with what we are here to do.
0:17:41 Let me tell you, I have to be honest, there were moments in twenty-twenty, late twenty-twenty, early twenty-twenty-one, the middle of COVID, that we had usability studies and we had things planned and were being canceled because of the COVID epidemic.
0:17:54 It was challenging. It was-- there were lonely moments as an early-stage founder.
0:17:57 But luckily, I have a strong support of my co-founder, a great team that has been sticking with us for-- we have very limited turnover as a early-stage company, and also good investors that, that believe in our thesis and patient enough to let us do what we have to do to be able to, to get where we are today.
0:18:14 Yeah, no, that's, that's great stuff.
0:18:16 You hit on the, the importance of having strong support from your investors to be able to na- navigate a lot of those, a lot of those challenges, especially with developing kind of novel technology like what you're onto at Occur, at Occur Cardio.
0:18:27 But that's-- I love hearing that because I think it's so easy to see stories in various outlets around how this startup had an exit or, oh, this startup just raised another round, and the reality is it's very up and down, right?
0:18:37 [laughs] These, these journeys, and they're rarely, if ever, like smooth sailing.
0:18:42 And so I think that maybe that's the, the big take-home message or at least something that resonates hearing you describe your story over the past five years is that there's a certain level of, of persistence and, and that you need without a doubt.
0:18:53 Um, but, but also there's just-- there's gonna be a lot of ups and downs and, and that's to be expected when you're trying to pu- push a boulder uphill and trying to change how care, how care, kind of the care pathway in, in, in medicine.
0:19:04 With that said, we touched on this earlier, Juan, but the aortic stenosis, A-AK, AVS, the aortic stenosis screening tool that received breakthrough designation, that, like, that, that's huge.
0:19:14 And a- and again, congrats on that. That's, uh, that, that's, uh, that's really cool to see just because th- those are, those are just rare to come by. But for someone that's
0:19:22 f- someone f-fairly new to the reg clin process, talk to us a little bit about maybe what you got right or what you got wrong in order to not only get 510[k] clearance for your ECG product but also this new kind of novel screening tool.
0:19:35 I think what I got wrong is the speed how things can get done. I was naive to believe that I was going to move faster than I have moved.
0:19:48 In med tech, even software, with speed, the, the, the, the f- the f- fast is never an option. So it's slow, slower, or stop, right?
0:19:59 So that's, that, that-- those are the velocities that, the speed that we-- that the industry move, right? Because they're, they're clinical validation, regulatory quality, and going several iterations.
0:20:10 We're dealing with science. Sci- science is never linear, right? Sometimes you move two step forward, one backwards, right? So I think it's, I think the,
0:20:20 they said the biggest, um, misconception I had is, was that I could move much faster than I have moved.
0:20:27 And nevertheless, I have been mentioned by many people that we have done a lot in, in the-- with the time that we have as a company.
0:20:37 We have raised less than six million dollars and have had one clearance, one p- one paying customer, a few more coming, and a breakthrough designation, a few more in the pipeline. So that's not common to have.
0:20:47 So I think it's, we have been lucky enough to be able to move ef- have a good operation efficiently building this, and we have learned how to pr- improve the process to take an idea to prototyping validation.
0:21:02 So I think that's, that's, I think what, what I believe it's, um, our secret sauce, and we have been able to improve the process in which we can take an idea or research into reality in a very streamlined process, right?
0:21:15 We made some mistakes several years ago, but we have improved the process, the software, medical device, ECG space.
0:21:21 We do believe right now we have an unfair advantage with most people in the space because, um, of, of our experience of being, of, of we have been in the middle of the COVID pandemic, trying to build a company, having less resources.
0:21:33 Even myself, that I don't have a cur-- I, I don't have a background in the space, I could be dangerous in several regulatory areas that I had to learn from scratch.
0:21:43 It's a matter of time after dealing with so many times with regulatory consultants and quality management consultants and dealing with, uh, the regulators that, that you become dangerous enough to be able to derive process and focus on what is important.
0:22:00 Focus on where do you deliver value. Focus on how you see a potential partner.
0:22:06 So I think it's understanding where payers w- and what payers see it, the strategics see it, as well as providers, and understand the different pain points and the way you integrate into that.
0:22:19 I believe all that is right now, all that knowledge that we have built has helped us get where we are, and also we believe we're gonna move faster, and I, I'm going to announce great things in the next twelve to eighteen months.
0:22:36 Yeah. [laughs] I lo- I love that, that framework. It's not really fast and maybe fast and then slow. It's, no, it's slow, slower, [laughs] and then really slow or stopped it. Stop, yeah, at a screeching halt.
0:22:47 So that's-- that, that is a healthy reminder though because I think it can be really frustrating how slow sometimes things can feel.
0:22:53 But to your point about it's-- the better way to maybe think about it is how efficient we are with, with our resources. I think that's what's most important. Sometimes gets lost, right?
0:23:00 When maybe, uh, a competitor or someone else in the space raises a huge round, and it's, yeah, maybe that's a good thing.
0:23:06 But it also means from a business standpoint, it's a lot of dilution, and can they get to the next mi- major milestone for their company? Do they need that much more money, or can you do it in a, in a lean fashion?
0:23:16 So when, when you think about efficiency, are there-- has there been, like, uh, one or two things that have been really helpful in, in how you've run your company in a really efficient manner to get to these kind of two significant milestones with, like, very little money relatively?
0:23:29 [upbeat music] Hey, everyone. Let's take a quick break to talk about Fast Wave Medical, the company I co-founded and lead as CEO.
0:23:36 Our team is developing next-generation intravascular lithotripsy systems for complex calcific disease. This type of therapy is often referred to as IVL.
0:23:44 The market size for IVL is over nine billion dollars, and there's only one player in the space with a market cap of around ten billion. So naturally, there's a lot of investor interest in Fast Wave.
0:23:53 In fact, we opened up an opportunity to invest directly into the company almost a year ago, and we were blown away by the interest from our community.
0:24:00 So much so that we ended up closing eight million dollars from our supporters in less than a month. Typically, opportunities to invest in venture-backed startups like Fast Wave are pretty rare.
0:24:08 So based on significant and continued demand, we highly encourage you to sign up for our wait list to avoid missing out on the next opportunity to invest. You can opt in at fastwavemedical.com/invest.
0:24:19 And if this is the first time you're hearing about Fast Wave, here are some key highlights. As I mentioned before, we are sitting on an IVL market valued at over nine billion dollars with only one incumbent.
0:24:28 Second, we just completed our first in-human study with eight treated patients, resulting in 100% lesions crossed and a 93% reduction in mean diameter stenosis from baseline.
0:24:38 We've raised over $20 million to date from corporate venture and cardiovascular KOLs, and we have five granted patents by the USPTO and multiple FTOs.
0:24:46 If you're interested in empowering physicians with advanced IVL technology while potentially benefiting from a fast-growing IVL market, head over to fastwavemedical.com/invest and check out the details.
0:24:57 Again, that's fastwavemedical.com/invest. All right. Let's get back to the rest of the conversation. [upbeat music] Hindsight's always 20/20, but I believe that has been a blessing for us, that we...
0:25:11 First of all, we did not raise a large round in 2021, so we are not... 2021, the, or 2022 evaluations were, like, crazy. Second, we used the money when we had to,
0:25:25 and soon, when we go to a market and raise, we'll be raising to drive revenue and speed. Mm.
0:25:35 And from a ret- ROI perspective, we are-- it's a much better proposition as a company, as well myself as a founder and for my initial investors, protecting the value of the company and dilution.
0:25:48 For my, for myself, my co-founders, my employees, and my investors that are-- when we go to market, we're going to raise capital to commercialize at speed and velocity.
0:25:59 We already have a, a strong foundation of products already cleared, already enough traction. Having a pipeline to execute is not that we're, we're gonna be raising money just to strategize or brainstorm or build science.
0:26:13 We will continue to do that in the future because as a, as a, as a company in this space, you cannot be a one-trick pony. Mm.
0:26:19 I believe in order to add long-lasting value in any sector, but the med tech and software medical device, you have to have a portfolio of use cases and not rely on just one particular indication to be able to build value and, and a company to last.
0:26:38 Yeah. Yeah. That's, it's-- I think that's really important, and it stands out to me.
0:26:41 Hopefully it stands out to those listening that this, that, that advice, um, around es- especially around dilution, is coming from an expert in the space, right?
0:26:48 You spent a [chuckles] you spent a, a quite a bit of time as an investment banker, so you more than anyone would probably know the implications of that.
0:26:54 And, you know, if you-- I guess the best way to think about it from my standpoint is if you're staring down a $50 million in capital to get to a point where you're actually selling product, if 80% of that capital was used in the development versus maybe the opposite, where 80% is now being used to actually commercialize it, there's, there's gonna be a much, much stronger ROI in the latter scenario.
0:27:15 And yeah, so I think it's just really, it's really-- S-sometimes we, it's, it's just we, we get caught up in, in how much capital is being raised in a certain round and that, that's, that can be a vanity metric at the end of the day.
0:27:24 You, you cannot be blind of what's happening in the market, what's happening to competition and other people working on similar domain. You cannot be blind. You have to be mindful of that.
0:27:33 I always say I like to run scared, right? Always running, but looking on my back and see who may be approaching me.
0:27:39 But, but nevertheless, right now, as for us, it's, it's a really refreshing opportunity to s- to say when we go to investors, "Look at AccuCardia, what we have accomplished, at the pipeline that we have, what we're going to see compared to some other people trying to do stuff that have raised twenty, thirty, forty, fifty time more than us, and look to what they have accomplished."
0:28:02 And for a relative value basis, again, that's, again, having that ba- that transactional mindset help me unders- help me present this idea.
0:28:09 As a potential investor, look at these comps, how much they have raised, the implied valuation.
0:28:15 Look to what they have accomplished, and look at this company asking for money just to commercialize, asking for money just to finalize certain science already validated and developed.
0:28:26 And, and, and from you do the relative value, uh, analysis, it becomes a no-brainer. And luckily, we are in that position nowadays. Yeah. Yeah. I, I can tell maybe the passion about this topic.
0:28:37 You, you probably had to tell, reinforce that messaging, 'cause it's really important.
0:28:40 Because some, some-- the, the weird thing about a, a, a startup, and maybe this is more of a message to other founders or CEOs that are, that are running companies and trying to raise money is, make sure you do emphasize that.
0:28:49 If you're in the position where you've been really efficient, make that a strong point.
0:28:52 Even though a competitor may have raised two X the money and it looks impressive from a list of investors, that doesn't necessarily mean that they're in a good spot, right?
0:28:59 'Cause every bit of dilution that comes with all of that capital means they have to then exit potentially at a certain, at a much higher price point when there's less acquirers than at that point.
0:29:08 Let alone the i- the implications if they wanna commercialize and go at it alone in the future. Not always a good thing, right? To be raising a ton of capital. It's gotta be smart capital or stage- Yeah, and-...
0:29:18 appropriate capital.
0:29:19 Yeah, and also when we are building, when you're building innovations, bringing some investors too early to get inside the, the kitchen to, and get too close to the fire and, and provide too much opinions.
0:29:33 And sometimes it's good to, to let the science, let the, the innovators think on their own without too many in, uh, many opinions from outsiders that may not be an expert on what they're saying.
0:29:47 So to, to be able to craft their own story. I think that for us has been a blessing that we were pinned down working on our product, working on technology, understanding the needs of the market on our own terms.
0:30:00 And now that we are getting ready, now we can go and be, and be, and bring people from with other ideas and different minds and different mindsets to be able to get us get to the next phase of the company, which is
0:30:13 fast growth and, and multiple product lines. Yep. Yep, and I, and I'm sure you've probably gotten this 'cause I've gotten the same thing.
0:30:20 But you, you, you're a-- you got a little bit of a, an atypical background, but yet you ran a very su- you s- ran and scaled a very successful business previously.
0:30:28 And sometimes that If you have, if you, if you don't maybe have the classic background, don't be afraid of that, right? Because at, at the end of the day, you have a...
0:30:36 In your case, you have a strong story where you act- you, you did, you, you ran and scaled a, a profitable business. And 'cause I, I, I say this because I think it's important. I run into the same things.
0:30:43 I had a little bit of a, maybe a, an unusual background myself as a founder CEO, but the, the previous company I started, like, we, I, we funded that entirely ourselves. I didn't raise, raise capital.
0:30:53 Like, that business has generated over $100 million in top line revenues. I always point to that as an example because I don't... Like, that, that was a good thing that we didn't raise capital, right?
0:31:00 [laughs] The business- Yeah... still exists and it's, and it's a profitable, you know, venture.
0:31:04 That's, it should be the goal for all of us, or at least one of the goals for all of us that are building, building and, and building a startup. With that said, I wanna finish one more thought on this fundraising topic.
0:31:11 I would've, I guess I would've thought that you going in to pitch investors, let's take the, the market and the clinical lead out- outside of it.
0:31:18 Y- you more than most would have had a good sort of insight into kinda what these investors are thinking with your, with your investment banking background.
0:31:24 But give us a little bit of sense into what you've learned raising that approximately $6 million for, for the company.
0:31:30 Are there a few things that stand out or maybe, and maybe frame that up for a couple things that would be especially helpful, right, for other med tech founder CEOs that are raising money in this kinda seed to series A stage.
0:31:40 Yeah.
0:31:40 I, I, I think when you're starting any business, unless you are really lucky and, and find an institution willing to, to do it, you have to go to people that, that know you, people that know who you are, what you have accomplished.
0:31:54 Mm-hmm.
0:31:55 And the f- the first few checks come from people that know that failure is not an option, and you're gonna, you're gonna deliver on what you're promising or deliver on what you have or, or we have, you have envisioned, right?
0:32:10 The first few million dollars were like that. People that know the team really well, that understand that failures, you know, is not an option and, and, and, and believe in the capability to the team to execute.
0:32:23 So that's the first few million. Then once you have an initial foundation, then it become easier, right? Then you, you sell on the story, you sell on the potential, but, but the first few million has to come that way.
0:32:34 So for founders that, that have that kind of networks or turn to top their current network, that's great. For other founders, that's not an option, so you have to look into angels groups.
0:32:45 You may have to look into, uh, crowdfunding, or you may have to look into, if you are into science, you can l- look into SBIR or similar, or similar grant options available here in the US.
0:32:57 So those are the things, but I, I think in my case, given that
0:33:02 m- all the, most of the co-founders are AccuCardia are people that have accomplished careers, either in banking, running a company, being a, a former Accenture consultant.
0:33:12 So we have the resumes to show, and that was the initial way for us to fundraise.
0:33:17 We have accomplished, as you ment- as I mentioned, scaling a company, getting contracts with commercial payers, dealing with different healthcare insurance company, building large enterprise scale software platforms.
0:33:28 So we had that to show that help us get, uh, the first few millions, and then after that we had an initial foundation and baseline so we could sell the story, the potential and, and, and what we're trying to accomplish.
0:33:40 Mm. That's such a, such, such a valuable point, especially if that, that first money in, which is oftentimes the hardest to come by, right? You, you try to tackle maybe a new, a newer problem. You haven't...
0:33:51 You're pretty early probably in the product development and you're trying to ask for a couple of million bucks. It's really difficult. So I think to, to your point, it's much more...
0:33:59 It can be much more efficient to go right to the people that you have an existing relationship with because they know who you are, right? Because at the end, investing is personal.
0:34:07 All investors you speak, they say it's not. When you get a no, it is personal. Mm-hmm. That means they don't want to back you. They don't want, they don't want to back, back you as a...
0:34:16 What the company after it reach revenue, series B, series C is different, but at the seed, seed stage, pre-seed, and C is very personal. And what they mean, for whatever reason, whatever, they have pattern matching.
0:34:32 You didn't fit the pattern or they're not your friends or they're not friends of friends, and then they're not gonna invest in you.
0:34:37 So you have to be able to be stubborn enough to find f- sources and funding from different sources to be able to achieve the business or the venture you want to launch. Yeah. And at the end, it's all personal.
0:34:49 You have to make yourself, make yourself under- be able to understand that, because if you do not understand that, it, it become very difficult because there are great entrepreneurs, great idea, great product that never get funded.
0:35:02 Luck also sometimes plays and luck, planets aligning, right timing, but at the end it's personal. Yeah, yeah.
0:35:09 Su- such a good point, such a good point, and I think, uh, most of us in, that are listening probably understand the idea that y- y- or they've heard this, right?
0:35:15 Like, raising money, it's, it is about relationship building, but that relationship is at, it's oftentimes at a personal level, right?
0:35:21 I think it's almost more helpful to think about it as investment is personal, and if you're listening to this and you're like, "I don't have any relationships," right? "I can't go find a million bucks.
0:35:29 I don't have those type of contacts." I think may- maybe the take home is that just know that, okay, if y- if you do need to go do a bunch of cold emailing, in essence cold calling, for lack of a better description,
0:35:39 it's gonna take time to build that relationship, and you need to think about it within the context of this is personal and I need to instill trust, and how do I instill trust, right, over the course of time?
0:35:48 And oftentimes that's telling someone that you're gonna do something and then actually doing it and then following up, right? And to demonstrate that you can actually execute against what you, what you say.
0:35:57 And it's okay to get nos, and it's okay if you don't have those type of relationships, but know that it is personal, right?
0:36:02 Like you just mentioned and this, and, and you're gonna need to, you solve for that, which is solvable, right?
0:36:06 There's entrepreneurs that do that all, all the time, and don't be afraid of it, but just know, go, go into it eyes wide open. One, one other topic I wanted to cover too, Juan, is partnerships and collaborations, right?
0:36:14 AccuCardia has recently partnered with Lucerne Health, I think, and then another, there's been announced another strategic, strategic partnership with a MAWI if I'm pronouncing that, M-A-W-I.
0:36:23 I'm, I'm sure that's probably beneficial in a number of different reasons for the company, but how have you gone about establishing those types of collaborations?
0:36:29 I'm sure there's been a lot of thoughtful, it's been a pretty, pretty thoughtful approach. But, well, like how have you gone about that, and what has it meant for AccuCardia at this point in time?
0:36:37 Our relationship with Lucem Health, it's have been incredible because th-they are our first partner for our FDA cleared product.
0:36:45 Literally, weeks after we obtained clearance, we met Lucem Health after we, we completed the Mayo Clinic Platform Accelerate program, which is an accelerator program for AI companies in healthcare.
0:37:01 It's part of Mayo Clinic. Literally at the demo day, final demo day, we had to pres- we presented AccuCardia.
0:37:09 One senior person, key person at Lucem Health was in the audience, and we had to-- we started to build a pers- a relationship. The same as a-- same investors, building a personal relationship.
0:37:20 That relationship evolved over several months, and when they had an, a product they wanted to build to, to manage patient at risk for stroke and they needed a solution to-- that-- to analyze ECG,
0:37:35 we were the first people they called. So just adding that and having-- and they help us be able to use our FDA cleared product for a use case that we did not expect.
0:37:45 So we are using AccuECG, our FDA cleared product for our cardio monitoring business, to perform retrospective analysis on ECGs already stored in the healthcare system.
0:37:55 So we are-- so they go through the EHR, find patient with higher risk for stroke.
0:38:00 Once they find a patient that have a higher risk, they fetch the ECG, send it to us for analysis, and they have built a strong solution to be able to manage patients at, at risk for stroke and manage that particular for value-based care, population health management.
0:38:14 But h- building that relationship that started at demo day, the Mayo Clinic Platform Accelerate in Rochester, Minnesota, be able to start that relationship and over several months, it evolved to a commercial partnership.
0:38:26 So, so again, similar to getting through the investors, customers, and even, I mean, hiring employees is all to building relationships and building that one-to-one, uh, approach. Yeah.
0:38:37 H-uh, you-- when, when it comes to-- it sounds like you've, you've had a fair amount of success, right? Not only building relationships with investors, but also in, in, in-- through some of these partnerships.
0:38:45 Do-- are there a few things that, like, have been helpful in either in those experiences directly or even just, "Hey, I, I learned this.
0:38:52 I learned these couple things, right, earlier in my career, and those have always stuck."
0:38:55 What, what, what, what is it about what you've done or what you've experienced that have led to some of these fruitful, uh, fruitful, uh, relationships? I, I, I think, uh, m-my way of thinking is
0:39:07 you have to be transparent, sharing the great, the good, and the ugly with DNA. Because in an early-stage company, if a new product, the cracks are going to be seen very quickly.
0:39:22 So if you try to hide it or, or put some makeup on it- Yeah... you're going to be seen as dishonest a-and not be able to build a relational partnership. For me, I learned that early on in my career.
0:39:38 I have the same thesis in my current company. I think it's-- there as, as an early-stage company, the-- you don't have the same resources as a large strategic, as a large corporation.
0:39:48 You need to understand and share the areas that, that you may not be ready, but you can share the areas of the product, where it's, where it-- where they are.
0:39:59 So the counterparties that you're dealing with, they are-- they enjoy w- the fact that you are being transparent, and transparency is everything.
0:40:08 So it's-- it may-- I may lose one or two potential relationship, but they will come.
0:40:13 So I rather share the areas that may not be ready for partnership, but but that transparency helps, and at least it is helping for us building a strong pipeline that we can execute, and the relationship that we cannot do at this stage because the product may not have the features that we need.
0:40:29 They understand that in six to 12, nine months, they may be able to call back and, and, and develop the relationship. Yeah. Got it. That's good stuff.
0:40:37 You also-- the, the, the company, your team has been, has been involved in a couple different accelerators, won a couple awards, in-including the TCT Innovator Award for the, the aortic, uh, stenosis screening tool that we discussed earlier.
0:40:49 Oftentimes these types of-- wh-whether it's an, an award directly or a competition or an accelerator, there's a fair amount of work that leads into that and that resource allocation that you have to account for, et cetera.
0:41:00 And I'm sure there's benefits al-al-along the way. But how have you specifically leveraged some of these wins, right?
0:41:07 That AccuCardia has been, has been either exposed to or, or outright won, as an example with the, the TCT Innovator Award. Yeah.
0:41:14 G-Given as we started, given that AccuCardia's team doesn't come from a traditional background in med tech,
0:41:24 so you have to expose the company, the technology, the team to, to key organizations to be able to get, get the recognition of the peers in the industry.
0:41:38 And I believe the fact that we have been able to get in, into MedTech Innovator, which is an amazing program that, that we learn a lot. We're exposed to great mentors, and we were able to get accepted and had been key.
0:41:55 The same with Mayo Clinic Platform Accelerate to be able to get brand association, access to mentorship, access to data to be able to complement some of the strengths that we have with resources that, that we can get from some of these organizations.
0:42:09 And I would-- any-anyone in med-- in med tech, they must apply to MedTech Innovator. It's a, it's a rite of passage- Hmm... if you are in the space.
0:42:18 And for us, being a pure software play is challenging because even though traditional med tech investor, they say they get software, but they really do not.
0:42:29 They love to, to touch and feel the, the gadgets and their investments.
0:42:34 So for us, it was great and challenging to be able to craft a story to convince the med, the med tech community to, to get accepted into MedTech Innovator.
0:42:44 And then as part of that- We were nominated to the Execution Award as part of like the innovator and being the only software company nominated made us really happy.
0:42:53 The same with Mayo Clinic Practice and Accelerator, which a great program to be able to get access to mentors and luminaries from Mayo Clinic, as well as getting access to clinical data that, that help us move faster in the clinical validation of the technology that we have.
0:43:08 So the way we're doing going by is that we compensate the fact that we may not come from traditional source, traditional backgrounds with over-validation of more data and showing more results than anybody else.
0:43:22 So for our FDA cleared product, our clinical validation showed to FDA was four times larger sample than our predicate. Hmm. Yeah.
0:43:34 So just because we wanted to make a point to FDA and also make a point of for potential customers that we have to overdo it to be able to show the, the capability of our technology. Yeah.
0:43:46 Yeah, I love that you just lean into that. You're not afraid and don't play the... This sounds may- this is maybe not the best description, but almost like the victim card, right?
0:43:53 "Well, there, why do I need to prove more? I'm, I'm just as good."
0:43:56 You just leaned into that, and it sounds like your, your approach right to our conversation earlier has allowed you to push through and think a little bit differently, right?
0:44:04 Not fall into certain dogmas that inherently exist in, in this space. Uh, but also you have a bit afraid of like the flip side of that.
0:44:10 Okay, we're, we can show more, we can do more, and we'll let the work prove it, you know, speak for itself. It sounds like that's worked out well for you.
0:44:17 And I, I, I like the idea too that look, a lot of these-- there's going to be unique opportunities, learnings, insights gleaned from all of these sort of, whether it's an accelerator or med tech in- innovator itself or even just a, an innovation con- contest at TCT.
0:44:31 But just the idea of you're using them to amplify, right, the brand, the company, right? Which is important, and I think a lot of startups miss out on that idea, right?
0:44:39 That kind of brand building i- is, is important even in the earliest stages. With that said, this is, this has been great. I love, I love your approach, Juan. I really do.
0:44:46 And so with that said, let's get to the rapid fire portion of this interview. But for, again, for everyone listening, AcuCardia is the company. It's A-C-U-R-K-A-R-D-I-A.
0:44:55 The link to it in the full write-up on MedSider will also lead to Juan's LinkedIn profile as well, so you can check out a little bit more on, more-- learn a little bit more about his background.
0:45:02 But with that said, rapid fire questions. Rapid fire in, in nature, but feel free to expand a little bit on your answers, Juan.
0:45:07 First one, when we fast-forward 12 months, so take us to late two thousand twenty-five, what are you most excited about at AcuCardia?
0:45:14 I'm more-- most excited about having deploy-- already deployed in the market the aortic stenosis screening model.
0:45:20 I think that's gonna be game changer, and even with the research published in TCT just a few days ago, I believe we can make a big difference to be able to find patients before they become symptomatic or become severe stenosis, so they can be managed earlier and saving lives.
0:45:37 That's what really helps me, uh, wake up every morning and really get motivated into this.
0:45:42 So I believe that by late twenty-five we have that in the market and the AccuECG, our cardiac monitoring product, already deployed five, seven customers by then.
0:45:53 Right now we have one, but four to five more by then have more people been targeted and using our technology, so patients can be managed earlier and saving life, which what I love. Yeah.
0:46:06 Yeah, it's a good mix of being able to see your product being used in a clinical setting while also still working and pushing another kind of technology ahead. It's a cool time for sure for the company.
0:46:14 Since, since co-founding AcuCardia five-plus years ago now, what's the most surprising thing that you've learned? Anything healthcare, anything med tech takes time, so be patient and persevere.
0:46:25 And also, always get a pre-submission meeting with FDA. So going through a filing without a pre-sub, not a good idea. Got it. All right. Next question.
0:46:34 K- kind of similar, but if you had a l- room full of, of life science entrepreneurs, maybe it's a mix of kinda hardware, med tech, maybe it's a little bit of software, med tech, maybe some health tech in there as well.
0:46:44 What-- If you wanted to leave them with one thing that would best position their startup for success, what would, what would that be? Get-- Try to get potential user, potential customer feedback early on, but don't
0:46:59 rely hundred percent on that feedback.
0:47:01 Sometimes as a, as an entrepreneur, as an innovator, as a billionaire, you have to know what the customer may need, and you have to be able to f- foresee yourself and foresee the product five steps ahead.
0:47:14 Uh, and don't get discouraged by early feedback that, that, that may need-- the market may not be ready at the moment, but you need to see yourself three or four or five months ahead. Hmm.
0:47:24 And have that back and forth capacity of getting the feedbacks, incorporation of the feedback, but still understanding that your technology may be, uh, uh, uh, four or five steps ahead.
0:47:37 That balance is, is tough to have, but you ha- you gotta have it if, if you are, if, if you're trying to deploy something at least in healthcare, which sometimes the customer may not know they need that product at that moment, but you need to know how to do it and deploy it.
0:47:50 Yeah. Good stuff. All right, last question. Let's start it, start over in your maybe, let's say your mid-twenties, uh, maybe shortly after an undergrad.
0:47:57 You're in the ear- early, early parts of your, your professional career. Um, is there anything that you'd tell-- whisper in the, the ears of the younger Juan Jimenez at that point?
0:48:06 I wish I had moved to healthcare sooner. I moved when I turned thirty-four, but I wish I started sooner. Ah. All right. Good way to wrap it up. Juan, I can't thank you enough.
0:48:18 I'll have you hold on the line, but I can't thank you enough for coming on the program. No, thank you, Scott, for the opportunity. Looking forward to listen to the podcast. Yeah, yeah.
0:48:25 And I'm, and I was just saying this, you're a smart entrepreneur. I love the, a lot of the insights you shared about the way you go about running your company.
0:48:31 So with that said, for everyone listening, again, AcuCardia is the website. Highly encourage everyone to check out. It's really cool technology. We'll link to it in the full write-up on MedSider.
0:48:38 And also, if you're new to the program, those write-ups are really helpful, right? Gives you a chance to read through a summary of a lot of the, the key learnings that Juan shared throughout this discussion.
0:48:46 Highly encourage you to check that out too. With that said, everyone, thanks for your listening attention as always. Until the next episode of MedSider Goes Live, everyone, take care.
0:48:52 [upbeat music] Hey, it's Scott again. One quick thing before you go. You see, I love bringing you insightful conversations with the best founders and CEOs of medical device and health technology startups.
0:49:01 But here's the thing, I'd be super grateful if you could help me reach even more ambitious doers who share our passion.
0:49:06 So if you found value in this podcast, if you found yourself nodding your head while listening, or if you simply enjoy what we're doing with MedSider, please take a moment to leave us a review. It's super easy.
0:49:15 Just open your Apple Podcasts app or the podcasts app of your choice, search for our show, and scroll down to the ratings and reviews section.
0:49:21 Leave your honest thoughts, and hit that five-star rating if you think we're worthy.
0:49:25 Your feedback is incredibly important and it's the best way to ensure we keep bringing you awesome discussions with leading founders and CEOs. So take a moment to be a good friend and leave that review today.
0:49:33 As always, thanks for being a part of our journey and for helping MedSider continue to grow and evolve. Your support is greatly appreciated. All right, enough talk about reviews.
0:49:40 Stay tuned for another informative episode coming at you soon. [upbeat music]
